Insights into Special Novelties in Thyroid Oncology Management
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 12438
Special Issue Editors
Interests: central venous catheter port; PICC line; superior vena cava syndrome; head and neck cancer; thyroid malignancy; fine needle aspiration cytology; core needle biopsy; thoracic oncology
Special Issues, Collections and Topics in MDPI journals
Interests: endocrine tumors; percutaneous thermal ablation
Special Issue Information
Dear Colleagues,
The aim of this Special Issue regarding is to report the recent innovations regarding the full diagnosis and management of the wide spectrum of thyroid malignancies.
The most common oncology types are of good prognosis, including papillary and follicular carcinomas, often grouped together and referred to as well-differentiated thyroid cancers representing roughly three-quarters of thyroid malignancies. Medullary thyroid carcinomas, metastases to the thyroid gland, dedifferentiated thyroid cancers, malignant thyroid lymphomas, and anaplastic carcinomas are of less and less favorable prognosis.
This issue will leave full expression for fine needle aspiration (FNA) cytology new scoring, novel Bethesda system, novel histopathology classification of thyroid malignancies, and emphasize the utility of thyroid nodule FNA calcitonin assay to reach a full diagnosis of medullary thyroid microcarcinoma.
Novel techniques of thyroid surgery aim to be minimally invasive and spare the thyroid organ as far as possible. They include the management of robotic surgery as well as dedicated and limited lymph node surgical dissection techniques.
On the one hand, papillary microcarcinoma patients may be eligible for minimally invasive surgery, percutaneous thermal ablation in dedicated cases (case-by-case basis), or even active surveillance. On the other hand, extensive surgery indication should be discussed in larger aggressive tumors in the absence of contraindication, in association with radio iodine therapeutic scintigraphy, radiation therapy and/or chemotherapy/immunotherapy.
This Special Issue also will provide insights into novel scintigraphy techniques and indications, an overview of radiation therapy techniques and indications in the “good, bad and ugly thyroid gland”, novelties in medical oncology therapies, including immunotherapy and the novel place of thyrosine kinase inhibitors in the management of anaplastic thyroid carcinomas.
Some fairly typical clinical cases will highlight the role of pre-operative ultrasound diagnosis of jugular vein invasion (to be included in the pre-operative checklist) by using novel technology, of an exceptional Richter thyroid syndrome diagnosed by using ultrasound-guided percutaneous biopsy and report a clinical reversible paraneoplastic syndrome of malignant thyroid origin.
At last, an update on percutaneous thermo ablative procedure techniques of papillary microcarcinomas and distant metastasis in oligo metastatic cancer patients will be discussed.
Suggested themes and article types for submissions
In this Special Issue, original research articles and reviews are welcome.
Research areas may include (but not limited to) the following:
- Novelties in pre operative ultrasound diagnosis of thyroid malignancy.
- Early diagnosis of thyroid malignancy.
- Microcarcinomas of thyroid gland, diagnosis and management.
- Medullary thyroid carcinomas diagnosis in. the grey zone of serum calcitonin level.
- Optimal management of malignant lymphoma, anaplastic carcinomas of thyroid gland.
- Metastases to thyroid gland.
- Surgical treatment modalities in thyroid oncology.
- Radiation therapy novelties.
- Medical therapy novelties in aggressive thyroid tumors.
- Percutaneous thermal ablative techniques, past present and future.
We look forward to receiving your contributions.
Dr. Pierre Yves Marcy
Dr. Édouard Ghanassia
Prof. Dr. Enrico Papini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- papillary thyroid carcinoma
- radiation therapy
- thyroid microcarcinoma
- Bethesda system
- fine needle aspiration
- calcitonin assay
- anaplastic carcinoma
- malignant lymphoma
- immunotherapy
- medullary thyroid carcinoma
- venous malignant thrombus
- percutaneous thermal ablation
